Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial-Reference-Cited by-同舟云学术

Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial

Published:2018-07 Issue:7 Volume:19 Page:904-915
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Tripathy Debu,Im Seock-Ah,Colleoni Marco,Franke Fabio,Bardia Aditya,Harbeck Nadia,Hurvitz Sara A,Chow Louis,Sohn Joohyuk,Lee Keun Seok,Campos-Gomez Saul,Villanueva Vazquez Rafael,Jung Kyung Hae,Babu K Govind,Wheatley-Price Paul,De Laurentiis Michelino,Im Young-Hyuck,Kuemmel Sherko,El-Saghir Nagi,Liu Mei-Ching,Carlson Gary,Hughes Gareth,Diaz-Padilla Ivan,Germa Caroline,Hirawat Samit,Lu Yen-Shen

Publisher

Elsevier BV

Subject

Oncology

Reference32 articles.

1. Global cancer statistics, 2012;Torre;CA Cancer J Clin,2015

2. Cancer statistics, 2017;Siegel;CA Cancer J Clin,2017

3. Breast cancer statistics, 2017, racial disparity in mortality by state;DeSantis;CA Cancer J Clin,2017

4. Incidence and mortality of female breast cancer in the Asia-Pacific region;Youlden;Cancer Biol Med,2014

5. Trends in epidemiology and management of breast cancer in developing Arab countries: a literature and registry analysis;El Saghir;Int J Surg,2007

Cited by 710 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The impact of previous therapy on overall-survival in registration clinical trials for 1st line metastatic breast cancer a systemic review;Critical Reviews in Oncology/Hematology;2024-10

2. Dronedarone inhibits the proliferation of esophageal squamous cell carcinoma through the CDK4/CDK6-RB1 axis in vitro and in vivo;Frontiers of Medicine;2024-09-13

3. Dose reduction and discontinuation due to the combination of CDK4/6 inhibitors and endocrine drugs: a systematic review and meta-analysis;European Journal of Clinical Pharmacology;2024-09-13

4. The choice of optimal therapy for ER+ HER2-metastatic breast cancer (PROMETHEUS): all-Russian analysis of physicians’ preferences – updated survey results;Medical alphabet;2024-09-05

5. Palbociclib: Randomized Studies and Real-world Evidence as the Basis for Therapeutic Planning in Metastatic Breast Cancer;Geburtshilfe und Frauenheilkunde;2024-09